HC Wainwright & Co. Maintains Buy on Genmab, Lowers Price Target to $46
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $51 to $46.
Morgan Stanley Maintains Underweight on Genmab, Lowers Price Target to $34
Morgan Stanley analyst Matthew Harrison maintains Genmab (NASDAQ:GMAB) with a Underweight and lowers the price target from $35 to $34.
SVB Leerink Maintains Market Perform on Genmab, Raises Price Target to $36
SVB Leerink maintains Genmab (NASDAQ:GMAB) with a Market Perform and raises the price target from $33 to $36.
Genmab Showcaseed Data From Robust Development Program Evaluating Epcoritamab in Patients Across a Broad Range of B-Cell Lymphomas at ASH 2022
Genmab A/S (Nasdaq: GMAB) today announced the results from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in combination with other therapies for the treatment of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 108 stocks hit new 52-week highs.
Genmab Announces FDA Acceptance For Priority Review Biologics License Application For Epcoritamab For The Treatment Of Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab BLA accepted for FDA Priority review; FDA action date is May 21, 2023
Epcoritamab could become the first subcutaneous bispecific antibody approved for the treatment of LBCL
BLA submission supported by
Epcoritamab BLA accepted for FDA Priority review; FDA action date is May 21, 2023
Morgan Stanley Maintains Underweight on Genmab, Raises Price Target to $34
Morgan Stanley analyst Matthew Harrison maintains Genmab (NASDAQ:GMAB) with a Underweight and raises the price target from $31 to $34.
SVB Leerink Maintains Market Perform on Genmab, Raises Price Target to $33
SVB Leerink analyst Jonathan Chang maintains Genmab (NASDAQ:GMAB) with a Market Perform and raises the price target from $31 to $33.
